{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:31:12Z","timestamp":1794047472093,"version":"4.8.0"},"reference-count":50,"publisher":"Ferrata Storti Foundation (Haematologica)","issue":"9","license":[{"start":{"date-parts":[[2024,5,9]],"date-time":"2024-05-09T00:00:00Z","timestamp":1715212800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["haematol"],"abstract":"<jats:p>Patients with primary immune thrombocytopenia (ITP) suffer from reduced survival and quality of life, but the underlying reasons for this are largely undescribed. Mental health and the use of psychotropic drugs in ITP is unknown. We investigated the risk of hospital-registered mental health events including fatigue and the use of psychotropic drugs in adult patients with ITP compared with the general population, using nationwide registry-data. We identified 3,749 patients with ITP and 149,849 age- and sex-matched general population comparators in the Danish Health Registries in the period 1997-2016. The median age was 60 years (interquartile range [IQR], 40-73) and 53% were women. We followed the individuals for incident mental health events and estimated the use of psychotropic drugs over calendar-years and in temporal relation to diagnosis of ITP. The first year cumulative incidence of any mental health event was 2.3% (95% confidence interval [CI]: 1.9-2.9) in patients and 0.7% (95% CI: 0.6-0.7) in comparators, yielding an adjusted cause-specific hazard ratio (csHR) of 3.57 (95% CI: 2.84-4.50). The corresponding estimates for depression were 1.2% (95% CI: 0.9-1.6) and 0.3% (0.3-0.4) respectively, with an adjusted csHR of 3.53 (95% CI: 2.56-4.85). We found similar findings for anxiety and fatigue, but risks generally diminished after 1-5 years. The use of opioids, antidepressants, and benzodiazepines increased in temporal relation to diagnosis of ITP. The risk of mental health events and the use of psychotropic drugs is higher in adult patients with ITP compared with the general population, and has a temporal relation to diagnosis of ITP emphasizing that mental health in ITP is a concern.<\/jats:p>","DOI":"10.3324\/haematol.2024.285364","type":"journal-article","created":{"date-parts":[[2024,5,9]],"date-time":"2024-05-09T04:16:41Z","timestamp":1715228201000},"page":"2944-2954","source":"Crossref","is-referenced-by-count":3,"title":["Mental health and use of psychotropic prescription drugs in adult patients with primary immune thrombocytopenia: a nationwide population-based cohort study"],"prefix":"10.3324","volume":"109","author":[{"given":"Nikolaj","family":"Mannering","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dennis Lund","family":"Hansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anton","family":"Potteg\u00e5rd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kjeld","family":"Andersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henrik","family":"Frederiksen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1856","published-online":{"date-parts":[[2024,5,9]]},"reference":[{"key":"65909","doi-asserted-by":"crossref","unstructured":"Provan D, Semple JW. Recent advances in the mechanisms and treatment of immune thrombocytopenia. EBioMedicine. 2022; 76:103820.","DOI":"10.1016\/j.ebiom.2022.103820"},{"key":"65910","doi-asserted-by":"crossref","unstructured":"Cines DB, Bussel JB, Liebman HA, Luning Prak ET. The ITP syndrome: pathogenic and clinical diversity. Blood. 2009; 113(26):6511-6521.","DOI":"10.1182\/blood-2009-01-129155"},{"key":"65911","doi-asserted-by":"crossref","unstructured":"Cines DB, Liebman H, Stasi R. Pathobiology of secondary immune thrombocytopenia. Semin Hematol. 2009; 46(1 Suppl 2):S2-14.","DOI":"10.1053\/j.seminhematol.2008.12.005"},{"key":"65912","doi-asserted-by":"crossref","unstructured":"Lawrie DA, Mannering N, Hansen DL, Frederiksen H. Time trends in incidence and prevalence of immune thrombocytopenia: a nationwide cohort analysis. Br J Haematol. 2023; 202(3):690-692.","DOI":"10.1111\/bjh.18886"},{"key":"65913","doi-asserted-by":"crossref","unstructured":"Salive ME. Multimorbidity in older adults. Epidemiol Rev. 2013; 35:75-83.","DOI":"10.1093\/epirev\/mxs009"},{"key":"65914","doi-asserted-by":"crossref","unstructured":"Norgaard M, Jensen AO, Engebjerg MC. Long-term clinical outcomes of patients with primary chronic immune thrombocytopenia: a Danish population-based cohort study. Blood. 2011; 117(13):3514-3520.","DOI":"10.1182\/blood-2010-10-312819"},{"key":"65915","doi-asserted-by":"crossref","unstructured":"McMillan R, Bussel JB, George JN, Lalla D, Nichol JL. Self-reported health-related quality of life in adults with chronic immune thrombocytopenic purpura. Am J Hematol. 2008; 83(2):150-154.","DOI":"10.1002\/ajh.20992"},{"key":"65916","doi-asserted-by":"crossref","unstructured":"Mannering N, Hansen DL, Pottegard A, Frederiksen H. Survival in adult patients with chronic primary and secondary immune thrombocytopenia: a population-based study. Transfusion. 2023; 63(2):415-426.","DOI":"10.1111\/trf.17212"},{"key":"65917","doi-asserted-by":"crossref","unstructured":"Sestol HG, Trangbaek SM, Bussel JB, Frederiksen H. Health-related quality of life in adult primary immune thrombocytopenia. Expert Rev Hematol. 2018; 11(12):975-985.","DOI":"10.1080\/17474086.2018.1548930"},{"key":"65918","doi-asserted-by":"crossref","unstructured":"Mathias SD, Gao SK, Miller KL. Impact of chronic Immune Thrombocytopenic purpura (ITP) on health-related quality of life: a conceptual model starting with the patient perspective. Health Qual Life Outcomes. 2008; 6:13.","DOI":"10.1186\/1477-7525-6-13"},{"key":"65919","doi-asserted-by":"crossref","unstructured":"Frederiksen H, Maegbaek ML, Norgaard M. Twenty-year mortality of adult patients with primary immune thrombocytopenia: a Danish population-based cohort study. Br J Haematol. 2014; 166(2):260-267.","DOI":"10.1111\/bjh.12869"},{"key":"65920","doi-asserted-by":"crossref","unstructured":"Sandvad M, Pedersen EA, Frederiksen H, Mannering N. Risk of infection in adult patients with primary immune thrombocytopenia (ITP): a systematic review. Expert Rev Hematol. 2021; 14(10):961-974.","DOI":"10.1080\/17474086.2021.1976635"},{"key":"65921","doi-asserted-by":"crossref","unstructured":"Grover S, Sahoo S, Rijal R, Mehra A. Don\u2019t forget me in amidst of COVID-19 pandemic: a case series and review of literature on steroid associated psychiatric manifestations. Brain Behav Immun Health. 2021; 18:100345.","DOI":"10.1016\/j.bbih.2021.100345"},{"key":"65922","doi-asserted-by":"crossref","unstructured":"McGrath P, Holewa H. The emotional consequences of corticosteroid use in hematology: preliminary findings. J Psychosoc Oncol. 2010; 28(4):335-350.","DOI":"10.1080\/07347332.2010.485246"},{"key":"65923","doi-asserted-by":"crossref","unstructured":"Frederiksen H, Ghanima W. Response of first line treatment with corticosteroids in a population-based cohort of adults with primary immune thrombocytopenia. Eur J Intern Med. 2017; 37:e23-e25.","DOI":"10.1016\/j.ejim.2016.09.001"},{"key":"65924","doi-asserted-by":"crossref","unstructured":"Ge L, Yap CW, Ong R, Heng BH. Social isolation, loneliness and their relationships with depressive symptoms: A population-based study. PLoS One. 2017; 12(8):e0182145.","DOI":"10.1371\/journal.pone.0182145"},{"key":"65925","doi-asserted-by":"crossref","unstructured":"Mitchell E, Frith J, Newton J. Fatigue and cognitive impairment in immune thrombocytopenic purpura remain stable over time: short report from a longitudinal study. Br J Haematol. 2019; 186(5):777-781.","DOI":"10.1111\/bjh.15993"},{"key":"65926","doi-asserted-by":"crossref","unstructured":"Arnold DM. Bleeding complications in immune thrombocytopenia. Hematology Am Soc Hematol Educ Program. 2015; 2015:237-242.","DOI":"10.1182\/asheducation-2015.1.237"},{"key":"65927","doi-asserted-by":"crossref","unstructured":"Zhou Z, Yang L, Chen Z. Health-related quality of life measured by the Short Form 36 in immune thrombocytopenic purpura: a cross-sectional survey in China. Eur J Haematol. 2007; 78(6):518-523.","DOI":"10.1111\/j.1600-0609.2007.00844.x"},{"key":"65928","doi-asserted-by":"crossref","unstructured":"Cooper N, Kruse A, Kruse C. Immune thrombocytopenia (ITP) World Impact Survey (I-WISh): impact of ITP on health-related quality of life. Am J Hematol. 2021; 96(2):199-207.","DOI":"10.1002\/ajh.26036"},{"key":"65929","doi-asserted-by":"crossref","unstructured":"Cooper N, Kruse A, Kruse C. Immune thrombocytopenia (ITP) World Impact Survey (iWISh): patient and physician perceptions of diagnosis, signs and symptoms, and treatment. Am J Hematol. 2021; 96(2):188-198.","DOI":"10.1002\/ajh.26045"},{"key":"65930","doi-asserted-by":"crossref","unstructured":"Newton JL, Reese JA, Watson SI. Fatigue in adult patients with primary immune thrombocytopenia. Eur J Haematol. 2011; 86(5):420-429.","DOI":"10.1111\/j.1600-0609.2011.01587.x"},{"key":"65931","doi-asserted-by":"crossref","unstructured":"Mathias SD, Bussel JB, George JN, McMillan R, Okano GJ, Nichol JL. A disease-specific measure of health-related quality of life for use in adults with immune thrombocytopenic purpura: its development and validation. Health Qual Life Outcomes. 2007; 5:11.","DOI":"10.1186\/1477-7525-5-11"},{"key":"65932","doi-asserted-by":"crossref","unstructured":"Zielinski MR, Systrom DM, Rose NR. Fatigue, sleep, and autoimmune and related disorders. Front Immunol. 2019; 10:1827.","DOI":"10.3389\/fimmu.2019.01827"},{"key":"65933","doi-asserted-by":"crossref","unstructured":"Murphy GC, Athanasou JA. The effect of unemployment on mental health. J Occup Organ Psych. 1999; 72(1):83-99.","DOI":"10.1348\/096317999166518"},{"key":"65934","doi-asserted-by":"crossref","unstructured":"Mannering N, Hansen DL, Moulis G, Ghanima W, Pottegard A, Frederiksen H. Risk of fractures and use of bisphosphonates in adult patients with immune thrombocytopenia - a nationwide population-based study. Br J Haematol. 2024; 204(4):1464-1475.","DOI":"10.1111\/bjh.19301"},{"key":"65935","doi-asserted-by":"crossref","unstructured":"Moller S, Bliddal M, Rubin KH. Methodical considerations on adjusting for Charlson Comorbidity Index in epidemiological studies. Eur J Epidemiol. 2021; 36(11):1123-1128.","DOI":"10.1007\/s10654-021-00802-z"},{"key":"65936","doi-asserted-by":"crossref","unstructured":"Ho C, Feng L, Fam J, Mahendran R, Kua EH, Ng TP. Coexisting medical comorbidity and depression: multiplicative effects on health outcomes in older adults. Int Psychogeriatr. 2014; 26(7):1221-1229.","DOI":"10.1017\/S1041610214000611"},{"key":"65937","doi-asserted-by":"crossref","unstructured":"Pati S, Pati S, Akker MVD, Schellevis FFG, Jena S, Burgers JS. Impact of comorbidity on health-related quality of life among type 2 diabetic patients in primary care. Prim Health Care Res Dev. 2020; 21:e9.","DOI":"10.1017\/S1463423620000055"},{"key":"65938","doi-asserted-by":"crossref","unstructured":"Ducat L, Philipson LH, Anderson BJ. The mental health comorbidities of diabetes. JAMA. 2014; 312(7):691-692.","DOI":"10.1001\/jama.2014.8040"},{"key":"65939","doi-asserted-by":"crossref","unstructured":"Neunert C, Terrell DR, Arnold DM. American Society of Hematology 2019 guidelines for immune thrombocytopenia. Blood Adv. 2019; 3(23):3829-3866.","DOI":"10.1182\/bloodadvances.2019000966"},{"key":"65940","doi-asserted-by":"crossref","unstructured":"Hill QA, Newland AC. Fatigue in immune thrombocytopenia. Br J Haematol. 2015; 170(2):141-149.","DOI":"10.1111\/bjh.13385"},{"key":"65941","doi-asserted-by":"crossref","unstructured":"Weyrich AS, Zimmerman GA. Platelets: signaling cells in the immune continuum. Trends Immunol. 2004; 25(9):489-495.","DOI":"10.1016\/j.it.2004.07.003"},{"key":"65942","doi-asserted-by":"crossref","unstructured":"Semple JW, Italiano JE Jr, Freedman J. Platelets and the immune continuum. Nat Rev Immunol. 2011; 11(4):264-274.","DOI":"10.1038\/nri2956"},{"key":"65943","doi-asserted-by":"crossref","unstructured":"Duerschmied D, Suidan GL, Demers M. Platelet serotonin promotes the recruitment of neutrophils to sites of acute inflammation in mice. Blood. 2013; 121(6):1008-1015.","DOI":"10.1182\/blood-2012-06-437392"},{"key":"65944","doi-asserted-by":"crossref","unstructured":"Beikmann BS, Tomlinson ID, Rosenthal SJ, Andrews AM. Serotonin uptake is largely mediated by platelets versus lymphocytes in peripheral blood cells. Acs Chem Neurosci. 2013; 4(1):161-170.","DOI":"10.1021\/cn300146w"},{"key":"65945","doi-asserted-by":"crossref","unstructured":"Lopez-Vilchez I, Diaz-Ricart M, White JG, Escolar G, Galan AM. Serotonin enhances platelet procoagulant properties and their activation induced during platelet tissue factor uptake. Cardiovasc Res. 2009; 84(2):309-316.","DOI":"10.1093\/cvr\/cvp205"},{"key":"65946","doi-asserted-by":"crossref","unstructured":"Nordentoft M, Wahlbeck K, Hallgren J. Excess mortality, causes of death and life expectancy in 270,770 patients with recent onset of mental disorders in Denmark, Finland and Sweden. PLoS One. 2013; 8(1):e55176.","DOI":"10.1371\/journal.pone.0055176"},{"key":"65947","doi-asserted-by":"crossref","unstructured":"Melo APS, Dippenaar IN, Johnson SC. All-cause and cause-specific mortality among people with severe mental illness in Brazil\u2019s public health system, 2000-15: a retrospective study. Lancet Psychiatry. 2022; 9(10):771-781.","DOI":"10.1016\/S2215-0366(22)00237-1"},{"key":"65948","doi-asserted-by":"crossref","unstructured":"Plana-Ripoll O, Momen NC, McGrath JJ. Temporal changes in sex- and age-specific incidence profiles of mental disorders -a nationwide study from 1970 to 2016. Acta Psychiatr Scand. 2022; 145(6):604-614.","DOI":"10.1111\/acps.13410"},{"key":"65949","doi-asserted-by":"crossref","unstructured":"Edinoff AN, Nix CA, Hollier J. Benzodiazepines: uses, dangers, and clinical considerations. Neurol Int. 2021; 13(4):594-607.","DOI":"10.3390\/neurolint13040059"},{"key":"65950","unstructured":"Johnson B, Streltzer J. Risks associated with long-term benzodiazepine use. Am Fam Physician. 2013; 88(4):224-226."},{"key":"65951","doi-asserted-by":"crossref","unstructured":"Rosenqvist TW, Wium-Andersen MK, Wium-Andersen IK, Jorgensen MB, Osler M. Long-term use of benzodiazepines and benzodiazepine-related drugs: a register-based Danish Cohort Study on determinants and risk of dose escalation. Am J Psychiatry. 2024; 181(3):246-254.","DOI":"10.1176\/appi.ajp.20230075"},{"key":"65952","doi-asserted-by":"crossref","unstructured":"Nissen SK, Pottegard A, Ryg J. Trends of opioid utilisation in Denmark: a nationwide study. Drugs Real World Outcomes. 2019; 6(4):155-164.","DOI":"10.1007\/s40801-019-00163-w"},{"key":"65953","doi-asserted-by":"crossref","unstructured":"Pottegard A, Sorensen AMS, Olesen M, Rasmussen L. Opioid prescriber responsibility: a Danish drug utilization study. Br J Clin Pharmacol. 2023; 89(4):1425-1430.","DOI":"10.1111\/bcp.15595"},{"key":"65954","doi-asserted-by":"crossref","unstructured":"Forns J, Pottegard A, Reinders T. Antidepressant use in Denmark, Germany, Spain, and Sweden between 2009 and 2014: incidence and comorbidities of antidepressant initiators. J Affect Disord. 2019; 249:242-252.","DOI":"10.1016\/j.jad.2019.02.010"},{"key":"65955","doi-asserted-by":"crossref","unstructured":"Ovlisen AK, Jakobsen LH, Kragholm KH. Mental health among patients with non-Hodgkin lymphoma: a Danish nationwide study of psychotropic drug use in 8750 patients and 43 750 matched comparators. Am J Hematol. 2022; 97(6):749-761.","DOI":"10.1002\/ajh.26538"},{"key":"65956","doi-asserted-by":"crossref","unstructured":"Pryce CR, Fontana A. Depression in autoimmune diseases. Curr Top Behav Neurosci. 2017; 31:139-154.","DOI":"10.1007\/7854_2016_7"},{"key":"65957","doi-asserted-by":"crossref","unstructured":"Pottegard A, Schmidt SAJ, Wallach-Kildemoes H, Sorensen HT, Hallas J, Schmidt M. Data resource profile: the Danish National Prescription Registry. Int J Epidemiol. 2017; 46(3):798-798f.","DOI":"10.1093\/ije\/dyw213"},{"key":"65958","doi-asserted-by":"crossref","unstructured":"Harbi H, Pottegard A. Validation of the \u201cindication for use\u201d (INDO) variable in the Danish National Prescription Registry. Epidemiology. 2024; 35(1):1-6.","DOI":"10.1097\/EDE.0000000000001666"}],"container-title":["Haematologica"],"original-title":[],"link":[{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2024.285364\/76981","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2024.285364\/77433","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/11589\/76981","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:06:23Z","timestamp":1794045983000},"score":1,"resource":{"primary":{"URL":"https:\/\/haematologica.org\/article\/view\/haematol.2024.285364"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,9]]},"references-count":50,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2024,9,1]]}},"URL":"https:\/\/doi.org\/10.3324\/haematol.2024.285364","relation":{},"ISSN":["1592-8721","0390-6078"],"issn-type":[{"value":"1592-8721","type":"electronic"},{"value":"0390-6078","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5,9]]}}}